Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Blood Transfusion and Agglutination

Blood Transfusion and Agglutination

Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...

Disorders of Erythrocytes

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...

Rh Blood Group

Rh Blood Group

The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.

Hemorrhagic Stroke l: Introduction

Hemorrhagic Stroke l: Introduction

A hemorrhagic stroke is an acute neurological event that occurs when a weakened cerebral blood vessel ruptures, allowing blood to accumulate within or around the brain. The sudden release of blood forms a focal hematoma that increases intracranial pressure, displaces neural tissue, and can obstruct cerebrospinal fluid pathways. These effects may be compounded by intraventricular extension of the hemorrhage, cerebral edema, or compression of adjacent structures, all of which contribute to...

Erythropoiesis

Erythropoiesis

Red blood cells (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...

Hemorrhagic Stroke ll: Pathophysiology

Hemorrhagic Stroke ll: Pathophysiology

A hemorrhagic stroke develops when a cerebral blood vessel ruptures, allowing blood to escape into the surrounding brain tissue, as in intracerebral hemorrhage (ICH), or into the subarachnoid space, as in subarachnoid hemorrhage (SAH). Because the skull is a rigid compartment, the sudden presence of extravascular blood rapidly increases intracranial pressure and compresses adjacent neural structures, leading to immediate tissue injury and impaired cerebral perfusion.Mass Effect and Primary...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Non-myeloablative versus reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients aged ≥65: a study from the ALWP of EBMT.

Bone marrow transplantation·2026

Same author

Belimumab and alopecia areata: No clear safety signal in a multicentre case series and pharmacovigilance analysis.

Annales de dermatologie et de venereologie·2026

Same author

Diffuse alveolar hemorrhage in antiphospholipid syndrome: Clinical presentation and prognosis.

Respiratory medicine·2026

Same author

Severe corneal manifestations of graft-versus-host disease: Experience of a tertiary referral center.

The ocular surface·2024

Same author

Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study.

Bone marrow transplantation·2023

Same author

Sequential vs myeloablative vs reduced intensity conditioning for patients with myelodysplastic syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: a retrospective study by the chronic malignancies working party of the EBMT.

Bone marrow transplantation·2023

Search research articles

Related Experiment Video

Updated: Jun 24, 2026

Fast and Specific Assessment of the Halogenating Peroxidase Activity in Leukocyte-enriched Blood Samples

Fast and Specific Assessment of the Halogenating Peroxidase Activity in Leukocyte-enriched Blood Samples

Published on: July 28, 2016

[Paroxysmal nocturnal hemoglobinuria].

R Peffault de Latour¹, Z Amoura, G Socié

¹Unité Inserm, hôpital Saint-Louis, Paris, France.

La Revue De Medecine Interne

|March 24, 2009

Summary

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder caused by a gene mutation leading to red blood cell destruction. Diagnosis involves flow cytometry, and treatment varies from complement inhibitors to bone marrow transplantation.

Area of Science:

Hematology
Genetics
Immunology

Context:

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired disorder originating from a somatic mutation in the PIG-A gene.
This mutation results in a deficiency of glycosylphosphatidylinositol-anchored proteins (GPI-AP), crucial for complement regulation.
The absence of GPI-anchored proteins, such as CD59, leads to complement-mediated hemolysis.

Purpose:

To elucidate the pathophysiology, diagnosis, and treatment strategies for Paroxysmal nocturnal hemoglobinuria (PNH).
To differentiate between classic PNH and the aplastic anemia PNH syndrome (AA-PNH).
To highlight the significant impact of thrombotic events on patient outcomes.

Summary:

PNH is diagnosed via flow cytometry, detecting GPI-AP deficient cells, and presents as hemolytic anemia, marrow failure, or thrombosis.

More Related Videos

Induction of Eryptosis in Red Blood Cells Using a Calcium Ionophore

Induction of Eryptosis in Red Blood Cells Using a Calcium Ionophore

Published on: January 21, 2020

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Related Experiment Videos

Last Updated: Jun 24, 2026

Fast and Specific Assessment of the Halogenating Peroxidase Activity in Leukocyte-enriched Blood Samples

Fast and Specific Assessment of the Halogenating Peroxidase Activity in Leukocyte-enriched Blood Samples

Published on: July 28, 2016

Induction of Eryptosis in Red Blood Cells Using a Calcium Ionophore

Induction of Eryptosis in Red Blood Cells Using a Calcium Ionophore

Published on: January 21, 2020

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Classic PNH is treated with complement inhibitors like eculizumab, while AA-PNH may involve bone marrow transplantation or immunosuppressive therapy.

Thromboses, often in unusual sites, are a major life-threatening complication across both PNH subtypes, associated with poor prognosis.

Impact:

Advances in understanding PNH pathophysiology have led to targeted therapies, improving patient outcomes.
Eculizumab offers a promising treatment for classic PNH by inhibiting the complement cascade.
Effective management of thrombotic events and appropriate treatment selection (BMT, IST, or complement inhibition) are critical for improving prognosis in PNH patients.